Posted October 16, 2018 07:15:00Madison dental has completed its first round of clinical trials to assess the effectiveness of the new oral vaccine for preventing coronavirus in adults and children.
Key points:The new vaccine was approved by the US Food and Drug Administration on Monday, October 13 and will be administered to people aged between 12 and 20.
Its approval came on the same day that the US State Department approved the first dose of the vaccine for use in pregnant women.
The trial is due to last two years and is expected to conclude by 2020.
It is the first trial to use a new vaccine that contains the highly effective coronaviruses LAIV-A and CML-2, as well as a live virus vaccine.
The FDA is expected make an announcement on the vaccine in the coming weeks.
Madison has said it is working with the US Centers for Disease Control and Prevention and the US Environmental Protection Agency to get the vaccine into patients’ hands.
The company said the vaccines will be delivered in two-year cycles to people with or without a health insurance plan.
“The vaccines will include two live viruses, LAIV and CBL-2 and a virus vaccine, CML2, which is designed to be a live vaccine in humans,” the company said in a statement.”LAIV-1, CBL and CLL-1 are all safe and effective for the treatment of severe coronaviral disease.”
In the US, we are partnering with the CDC and the FDA to deliver the vaccine to our customers who are currently eligible for the vaccine.
“We are also working with other state and federal health agencies to ensure that our vaccines are available in the US.”
The company’s CEO, Richard Bannister, said the vaccine would not have any adverse effects on people with serious illnesses.
“If anyone has serious symptoms from an LAIV vaccination, we recommend a full return to work,” he said.
“There will be no adverse effects.
There are no known risks for people with chronic diseases or for people who have been immunocompromised.”
Mr Bannisters said the company had received no complaints about the vaccine so far.
“All our trials are completely independent and we have no involvement in any clinical trial that we undertake.
We have had no reports of any adverse reactions to LAIV or CML from our trials,” he added.
The new LAIV vaccine is the most advanced vaccine available to date and has been designed to reduce the virus’s ability to replicate in the body.
“It is a very potent vaccine.
It is not just a small amount of vaccine.
We have put it in doses that are over a hundred times larger than that,” Mr Bannings said.
A vaccine is usually given by injection.
A live vaccine, like the one Madison has created, has a slightly higher dose of virus that will not be spread by saliva.
The first dose has already been administered to hundreds of people in the United States, and a second trial is planned for October.
Madisons clinical trials for the LAIV vaccines were started in January, but the company has been unable to complete its first phase, which will involve a placebo-controlled trial.
Mr Bansons team had initially hoped to see a result in the second phase by the end of 2018, but he said he was “disappointed” that it was not happening.
“I was pretty confident that the results would be there, and I am not disappointed that they are not,” he told ABC News.
“But we will get it done.
We will get the results.
And we will continue to do our clinical trials, we will be ready.”
The US has one of the most robust vaccination programmes in the world.
The US government has already paid for a total of 8,857,737 doses of the LAIII vaccine, according to US News and World Report.
“They are giving out the vaccines for free,” Mr Madison said.
“It is so great.”
“They just want to get people vaccinated.
We want to vaccinate as many people as possible, we want to make sure they get all the vaccines.”
He said Madison was confident the trial would be complete by the second year of the trial, although he did not have a firm date.
“Obviously we want it to be done before the end and that is our intention,” he concluded.
Topics:vaccines-and-immunity,health,vaccines,vaccinations-and the-prescription-and/or-use-of,dental-diseases,vaccination,vaccinogenics-and‐science,vaccine-development-and_approval,united-statesFirst posted October 16,2018 07:05:00More stories from Queensland